Key result
Genetically elevated plasma homocysteine levels were not causally associated with the risk of atrial fibrillation (OR 0.972; 95% CI 0.919-1.027; P=0.308).
Why the study?
Although studies have shown an association between plasma homocysteine levels and AF, whether this relationship is causal remains unclear.
Do genetically elevated plasma homocysteine levels increase the risk of atrial fibrillation?
Observational (n=588,190)
Do genetically elevated plasma homocysteine levels increase the risk of atrial fibrillation?
Odds Ratio: 0.972 (95% CI 0.919–1.027)
p-value: p=0.308
This Mendelian randomization study found no evidence of a causal relationship between plasma homocysteine levels and the risk of atrial fibrillation.
No support for homocysteine modification in AF prevention; challenges observational links and leaves open alternative pathways.
BACKGROUND AND AIMS: Although several studies have shown an association between plasma homocysteine (Hcy) levels and atrial fibrillation (AF), the causality remains unclear. We undertook a Mendelian randomization (MR) study to investigate the causal association between Hcy and AF. METHODS AND RESULTS: Single-nucleotide polymorphisms (SNPs) which genome-wide significantly associated with plasma Hcy levels were obtained from a genome-wide meta-analysis (N = 44 147). MR analyses including the random-effect inverse variance-weighted (IVW) meta-analysis, weighted median analysis, and MR-Egger regression were used to estimate the associations between the selected SNPs and AF based on a meta-analysis of genome-wide association study for AF (N = 588 190). The MR analyses revealed no causal role of genetically elevated plasma Hcy levels with AF risk (random-effect IVW, odds ratio per 1 SD increase in Hcy levels = 0.972, 95% confidence interval = 0.919 to 1.027, P = 0.308). The results were consistent with the weighted median method, MR-Egger and the analysis after excluding the pleiotropic SNPs. No heterogeneity and directional pleiotropy were observed in sensitivity analyses. CONCLUSION: The findings suggested that plasma Hcy levels were not causally associated with AF.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) conducted an observational in Atrial fibrillation (n=588,190). Plasma homocysteine levels was evaluated on Atrial fibrillation risk (OR 0.972, 95% CI 0.919-1.027, p=0.308). Genetically elevated plasma homocysteine levels were not causally associated with the risk of atrial fibrillation (OR 0.972; 95% CI 0.919-1.027; P=0.308).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: